Bayer Pays $310M For European Rights To Heart Drug
By Yeji Jesse Lee · March 4, 2024, 7:23 PM EST
German pharmaceutical giant Bayer and public biopharmaceutical company BridgeBio announced Monday that they would form a $310 million partnership centered on the experimental heart drug acoramidis....
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login